This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Medicis CEO Keeps His Wits

He also left no doubt that Inamed's skin-care business was the biggest attraction for Medicis. The key to the Medicis bid is the experimental skin treatment, Reloxin, which is similar to Allergan's Botox. When Allergan made its offer for Inamed, it also said it would divest its rights to Reloxin to avoid antitrust concerns. Inamed licenses Reloxin from the French company Ipsen.

On Friday, when one analyst asked if Medicis would pursue Reloxin if the Medicis-Inamed deal falls through, Shacknai called Reloxin the "threshhold event" in its romance of Inamed. If Medicis wasn't convinced that Reloxin could be a star product, Medicis wouldn't have made a bid for Inamed, Shacknai said.

He also made it clear that Inamed's skin-care business was more of a lure than its breast-implant business. Inamed is dueling with Mentor (MNT) to get government approval to use silicone breast implants for cosmetic surgery.

Right now, silicone implants are restricted to a few uses, such as breast reconstruction for women who have undergone mastectomies. Mentor and Inamed sell silicone gel implants in foreign markets for cosmetic surgery. They also sell saline-filled implants in U.S. and foreign markets for cosmetic purposes.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
IMDC $0.03 2.31%
AGN $240.22 1.21%
MRX $0.00 0.00%
AAPL $125.56 1.90%
FB $83.86 0.67%


DOW 17,988.59 +275.93 1.56%
S&P 500 2,081.94 +20.92 1.02%
NASDAQ 4,937.6570 +46.4380 0.95%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs